ArticleO&G open2024
Patient Surveillance Adherence After Treatment for Endometrial Cancer.
Article in O&G open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess factors that may affect patients' adherence to recommended surveillance after treatment for endometrial cancer.
methodsWe performed a retrospective study of all patients undergoing primary treatment for endometrial cancer from January 1, 2010, to December 30, 2017, at a tertiary referral center. Patients were included for analysis if there was sufficient information in the electronic medical records. Patient demographic information, cancer characteristics, and surveillance adherence data were collected. The median inflation-adjusted income was calculated from the patients' ZIP codes and U.S. Census data. The primary outcome assessed was
resultsDuring the study period, 870 patients were included for analysis. The mean age at diagnosis and body mass index (BMI) of the entire cohort were 63.4 years and 35.8, respectively. Overall, 761 patients (87.5%) were adherent to the recommended surveillance guidelines. Patients who were not adherent to recommended surveillance lived significantly farther from the cancer center (39.2 miles vs 20.7 miles,
conclusionIncreased distance to a tertiary care center and lower median income were significantly associated with decreased adherence to recommended surveillance guidelines. This is consistent with current literature on increased distance traveled as a proxy for worse survival in gynecologic malignancies, as well as worse endometrial cancer outcomes in patients of lower socioeconomic status. This highlights an area of disparity that needs improvement and warrants further investigation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.